<scp>ASP</scp>8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with <i><scp>EGFR</scp></i> mutation‐positive non‐small‐cell lung cancerKoichi Azuma, Kazuhiko Nakagawa, Makoto Nishio et al.|Cancer Science|2018Cited by 35
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1Makoto Nishio, Hideaki Mizutani, Yuichiro Ohe et al.|International Journal of Clinical Oncology|2023Cited by 13
Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)Masahiro Seike, T. Nukiwa, A. Inoue et al.|Annals of Oncology|2018Cited by 10
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)Tetsuhiko Asao, Kazuhisa Takahashi, Takehito Shukuya et al.|Clinical Lung Cancer|2023Cited by 5
Thoracoscopic resection for a localized mesothelioma of the pleura; a case report.Shintaro Nakashima, Satoshi Ikeda, Tsuneo Okumichi et al.|The Journal of the Japanese Association for Chest Surgery|1997Cited by 0